 Medscape |
EU Committee Rejects Budesonide/Salmeterol Combo for Asthma
Medscape The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a negative recommendation on the marketing application for anti-asthma combination medication budesonide/salmeterol (Labazenit, … |
View full post on asthma – Google News